期刊文献+

利伐沙班片在急性冠状动脉综合征中的疗效及安全性研究 预览 被引量:2

Study on efficacy and safety of rivaroxaban tablets in acute coronary syndromes
在线阅读 免费下载
分享 导出
摘要 目的探讨利伐沙班片在急性冠状动脉综合征中的疗效及安全性。方法 70例急性冠状动脉综合征患者,随机分为试验组和对照组,各35例。对照组采用低分子肝素治疗,试验组采用利伐沙班片治疗。比较两组患者心血管事件和并发症发生情况。结果试验组心血管事件发生率为5.7%,对照组心血管事件发生率为22.9%,试验组心血管事件发生率低于对照组,差异有统计学意义(P〈0.05)。试验组并发症发生率为2.9%,对照组并发症发生率为17.1%,试验组并发症发生率低于对照组,差异有统计学意义(P〈0.05)。结论利伐沙班片治疗急性冠状动脉综合征疗效显著,安全性高,值得推广。 Objective To discuss the efficacy and safety of rivaroxaban tablets in acute coronary syndromes. Methods A total of 70 acute coronary syndromes patients were randomly divided into experimental group and control group, with 35 cases in each group. The control group was treated with low molecular heparin, and the experimental group was treated with rivaroxaban tablets. Comparison were made on occurrence of cardiovascular events and complications between two groups. Results The experimental group had incidence of of cardiovascular events as 5.7%, while the control group had incidence of cardiovascular events as 22.9%. The experimental group had lower incidence of cardiovascular events than the control group, and the difference was statistically significant(P〈0.05). The experimental group had incidence of complications as 2.9%, while the control group had incidence of complications as 17.1%. The experimental group had lower incidence of complications than the control group, and the difference was statistically significant(P〈0.05). Conclusion Rivaroxaban tablets shows remarkable efficacy in treating acute coronary syndromes with high safety, and is worthy of promotion.
作者 林琳 王力 LIN Lin, WANG Li. (Department of Internal Medicine-Cardiovascular, Dalian Friendship Hospital, Dalian 116001, China)
出处 《中国现代药物应用》 2018年第1期75-77,共3页
关键词 利伐沙班片 急性冠状动脉综合征 安全性 Rivaroxaban tablets Acute coronary syndromes Safety
  • 相关文献

参考文献12

二级参考文献188

  • 1张静.低分子肝素治疗急性冠脉综合征的观察与护理[J].当代医药论丛:下半月,2013,0(7):277-277. 被引量:3
  • 2翟振国,王辰,刘艳梅,秦志强.低分子肝素与普通肝素治疗急性肺血栓栓塞症疗效和安全性比较的Meta分析[J].中国医学科学院学报,2004,26(3):221-226. 被引量:10
  • 3周自强 ,胡大一 ,陈捷 ,张仁汉 ,李奎宝 ,赵秀丽 .中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1198
  • 4BECATTINI C, VEDOVATI MC, AGNELLI G, st al. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation : a review of the literature[ J]. Thromb Res, 2012, 129 (3): 392-400. 被引量:1
  • 5PERZBORN E, STRASSBURGER J, WILMEN A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 597939 an oral, direct factorXa inhibitor[ J]. J Thromb Haemost, 2005, 3(3): 514-521. 被引量:1
  • 6ROEHRIG S, STRAUB A, POHLMANN J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-( { (5S) -2-oxo-3-[ 4- ( 3 -oxomorpholin-4-yl ) phenyl J -1,3 -oxazolidin-5 -yl│ methyl ) thiophene-2-carboxamide ( BAY 59-7939) : an oral, direct factor Xainhibitorl Jl. J Med Chem, 2005, 48 (19) : 5900 - 5908. 被引量:1
  • 7KUBITZA D, BECKA M, VOITH B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939 an oral, direct factor Xa inhibitor [ J ]. Clin Pharmacol Ther 2005, 78(4) : 412 -421. 被引量:1
  • 8KUBITZA D, BECKA M, WENSING G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects[ J]. Eur J Clin Pharmacol, 2005, 61 (12) : 873 - 880. 被引量:1
  • 9AHMAD Y, LIP GY. Stroke prevention in atrial fibrillation: where are we now? [ J]. Clin Med Insights Cardiol,2012,6 : 65 - 78. 被引量:1
  • 10HANKEY GJ, PATEL MR, STEVENS SR, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF[J]. Lancet Neurol, 2012, 11(4) : 315 -322. 被引量:1

共引文献62

同被引文献6

引证文献2

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈